Perfume compositions – Perfume compositions – With preservative – stabilizer – or fixative
Reexamination Certificate
2006-04-25
2009-11-17
Yu, Misook (Department: 1642)
Perfume compositions
Perfume compositions
With preservative, stabilizer, or fixative
C424S134100
Reexamination Certificate
active
07618933
ABSTRACT:
Therapeutic uses of inhibitors of the Lymphotoxin Pathway to treat tumors, specifically to treat follicular lymphomas.
REFERENCES:
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5225538 (1993-07-01), Capon et al.
patent: 5661004 (1997-08-01), Browning et al.
patent: 5670149 (1997-09-01), Browning et al.
patent: 5795964 (1998-08-01), Browning et al.
patent: 5925351 (1999-07-01), Browning et al.
patent: 6312691 (2001-11-01), Browning et al.
patent: 6403087 (2002-06-01), Browning et al.
patent: 6669941 (2003-12-01), Browning et al.
patent: 7001598 (2006-02-01), Browning et al.
patent: 7030080 (2006-04-01), Browning et al.
patent: 7060667 (2006-06-01), Browning et al.
patent: 7255854 (2007-08-01), Browning et al.
patent: 7309492 (2007-12-01), Browning et al.
patent: 2002/0039580 (2002-04-01), Browning et al.
patent: 2004/0198635 (2004-10-01), Browning et al.
patent: 2005/0037003 (2005-02-01), Browning et al.
patent: 2005/0281811 (2005-12-01), Browning et al.
patent: 0873998 (1998-10-01), None
patent: WO-92/00329 (1992-01-01), None
patent: WO-94/04679 (1994-03-01), None
patent: WO-94/13808 (1994-06-01), None
patent: WO-96/01121 (1996-01-01), None
patent: WO-96/23071 (1996-08-01), None
patent: WO-97/03687 (1997-02-01), None
Alexopoulou, Lena et al., “Immunoregulatory Activities of Transmembrane TNF Revealed in Transgenic and Mutant Mice,”6th International TNF Congress, p. 228, Poster Presentation No. 110 (1996).
Androlewicz, Matthew J. et al., “Lymphotoxin Is Expressed as a Heteromeric Complex with a Distinct 33-kDa Glycoprotein on the Surface of an Activated Human T Cell Hybridoma,”The Journal of Biological Chemistry, vol. 267(4):2542-2547 (1992).
Arulanandam, Antonio R.N. et al., “A Soluble Multimeric Recombinant CD2 Protein Identifies CD48 as a Low Affinity Ligand for Human CD2: Divergence of CD2 Ligands during the Evolution of Humans and Mice,”J. Exp. Med., vol. 177:1439-1450 (1993).
Banks, Theresa A. et al., “Lymphotoxin-α-Deficient Mice, Effects on Secondary Lymphoid Organ Development and Humoral Immune Responsiveness,”The Journal of Immunology, vol. 155:1685-1693 (1995).
Browning, Jeffrey L. et al., “Characterization of Surface Symphotoxin Forms, Use of Specific Monoclonal Antibodies and Soluble Receptors,”The Journal of Immunology, vol. 154:33-46 (1995).
Browning, Jeffrey L. et al., “Lymphotoxin and an Associated 33-kDa Glycoprotein are Expressed on the Surface of an Activated Human T Cell Hybridoma,”The Journal of Immunology, vol. 147:1230-1237 (1991).
Browning, Jeffrey L. et al., “Lymphotoxin β, a Novel Member of the TNF Family That Forms a Heteromeric Complex with Lymphotoxin on the Cell Surface,”Cell, vol. 72:847-856 (1993).
Browning, Jeffrey L. et al., “Signaling through the Lymphotoxin β Receptor Induces the Death of Some Adenocarcinoma Tumor Lines,”J. Exp. Med., vol. 183:867-878 (1996).
Crowe, Paul D. et al., “A Lymphotoxin-β-Specific Receptor,”Science, vol. 264:707-710 (1994).
De Togni et al. “Abnormal Development of Peripheral Lympoid Organs in Mice Deficient in Lymphotoxin”Science264:703-708 (1994).
Erickson, Sharon L. et al., “Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice,”Nature, vol. 372:560-563 (1994).
Ettinger, Rachel et al., “Disrupted splenic architecture, but normal lymph node development in mice expressing a soluble lymphotoxin-β receptor-IgG1 fusion protein,”Proc. Natl. Acad. Sci. USA, vol. 93:13102-13107 (1996).
Hagemeijer, A., “Cytogenetics and oncogenes,”Leukemia, vol. 6(Suppl. 4):16-18 (1992).
Higuchi, Masahiro et al., “Inhibition of Ligand Binding and Antiproliferative Effects of Tumor Necrosis Factor and Lymphotoxin by Soluble Forms of Recombinant P60 and P80 Receptors,”Biochemical and Biophysical Research Communications, vol. 182(2):638-643 (1992).
Hillion et al. (1993)Leukemia7(3):410-7.
Katz, Irene R. et al., “Growth of SJL / J-Derived Transplantable Reticulum Cell Sarcoma Related to Its Ability to Induce T-Cell Proliferation in the Host,”Cellular Immunology, vol. 65:84-92 (1981).
Lane, Peter et al., “Activated human T cells express a ligand for the human B cell-associated antigen CD40 which participates in T cell-dependent activation of B lymphocytes,”Eur. J. Immunol., vol. 22:2573-2578 (1992).
Lasky, J.L. et al., “Characterization and Growth Factor Requirements of SJL Lymphomas, I. Development of a B Cell Growth Factor-Dependent in Vitro Cells Line, cRCS-X,”The Journal of Immunology, vol. 14:679-687 (1988).
Lasky, Jennifer L. et al., “Characterization and growth factor requirements of SJL lymphomas, II. Interleukin 5 dependence of the in vitro cell line, cRCS-X, and influence of other cytokines,”Eur. J. Immunol., vol. 19:365-371 (1989).
Le Hir, Michel et al., “Differentiation of Follicular Dendritic Cells and Full Antibody Responses Require Tumor Necrosis Factor Receptor-1 Signaling,”J. Exp. Med., vol. 183:2367-2372 (1996).
Mackay, Fabienne et al., “Lymphotoxin but not tumor necrosis factor functions to maintain splenic architecture and humoral responsiveness in adult mice,”Eur. J. Immunol., vol. 27: 2033-2042 (1997).
Matsumoto, Mitsuru et al., “Affinity maturation without germinal centres in lymphotoxin-α-deficient mice,”Nature, vol. 382:462-466 (1996).
Matsumoto, Mitsuru et al., “Distinct Roles of Lymphotoxin α and the Type I Tumor Necrosis Factor (TNF) Receptor in the Establishment of Follicular Dendritic Cells from Non-Bone Marrow-derived Cells,”J. Exp. Med., vol. 186(12):1997-2004 (1997).
Matsumoto, Mitsuru et al., “Role of Lymphotoxin and the Type I TNF Receptor in the Formation of Germinal Centers,”Science, vol. 271:1289-1291 (1996).
Morrison, Sherie L. et al., “Chimerica human antibody molecules: Mouse antigen-binding domains with human constant region domains,”Proc. Natl. Acad. Sci. USA, vol. 81:6851-6855 (1984).
Morrison, Sherie L., “In Vitro Antibodies: Strategies for Production and Application,”Annu. Rev. Immunol., vol. 10:239-265 (1992).
Pasparakis, Manolis et al., “Immune and Inflammatory Responses in the TNFα Deficient Mice: A Critical Requirement for TNFα in Germinal Centre Formation and in the Maturation of the Humoral Immune Response,”Eur. Cytokine Netw., vol. 7(2):239, Poster Session No. 132 (1996).
Pfeffer, Klaus et al., “Mice Deficient for the 55 kd Tumor Necrosis Factor Receptor Are Resistant to Endotoxic Shock, yet Succumb toL. monocytogenesInfection,”Cell, vol. 73:457-467 (1993).
Picarella, Dominic E. et al., “Insulitis in transgenic mice expressing tumor necrosis factor β (lymphotoxin) in the pancreas,”Proc. Natl. Acad. Sci. USA, vol. 89:10036-10040 (1992).
Picker, Louis J. et al., “Physiological and Molecular Mechanisms of Lymphocyte Homing,”Annu. Rev. Immunol., vol. 10:561-591 (1992).
Ponzio, Nicholas M. et al., “Host-Tumor Interactions in the SJL Lymphoma Model,”Intern. Rev. Immunol., vol. 1:273-301 (1986).
Qin, Zhihai et al., “Human Lymphotoxin Has at Least Equal Antitumor Activity in Comparison to Human Tumor Necrosis Factor But Is Less Toxic in Mice,”Blood, vol. 85(10):2779-2785 (1995).
Queen, Cary et al., “A humanized antibody that binds to the interleukin 2 receptor,”Proc. Natl. Acad. Sci. USA, vol. 86:10029-10033 (1989).
Reisfeld, Ralph A. et al., “Involvement of B Lymphocytes in the Growth Inhibition of Human Pulmonary Melanoma Metastases in Athymicnu
uMice by an Antibody-Lymphotoxin Fusion Protein,”Cancer Research, vol. 56:1707-1712 (1996).
Rennert, P.D. et al., “Normal Development of Lymph Nodes is Disrupted by Soluble LT beta Receptor—Ig Fusion Protein,”European Cytokine Network, vol. 7(2):167, No. 17 (
Browning Jeffrey L.
Thorbecke Jeanette
Tsiagbe Vincent
Biogen Idec MA Inc.
Lahive & Cockfield LLP
Mandragouras Esq. Amy E.
New York University
Williams Megan E.
LandOfFree
Treatment of follicular lymphomas using inhibitors of the LT... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of follicular lymphomas using inhibitors of the LT..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of follicular lymphomas using inhibitors of the LT... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4075507